Exciting new developments at Quotient Bioresearch with announcement of deal with GE
Exciting new developments at Quotient Bioresearch with announcement of deal with GE
Quotient Bioresearch acquires radiochemical custom synthesis operations from GE Healthcare. Acquired business to provide Quotient-Amersham Radiochemicals branded products and services. Major investment in new radiochemicals facility to be located in Cardiff, Wales.
Quotient Bioresearch: High-throughput biomarker analysis delivers maximum information from each sample
Quotient Bioresearch highlights new approach at World Congress
At the recent Biomarker World Congress 2009, held in Philadelphia, USA, 27 – 29 May, Dr Craig Stovold, Senior Project Manager-Bioanalytical Sciences, Quotient Bioresearch, reported on how the company’s multiplexed assays are delivering more data, on a greater number of analytes and in a shorter time – getting as much information as possible from each sample.
QUOTIENT BIORESEARCH ACQUIRES EDINBURGH CLINICAL RESEARCH FACILITY
CAMBRIDGESHIRE, UK, 18th May 2009 – Quotient Bioresearch Limited
(“Quotient”), a leading provider of drug development services, today announces that it has acquired Charles River Laboratories’ (Charles River) Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years for Quotient. The Charles River facility, formerly Inveresk Clinical Research, will combine with Pharmaceutical Profiles, acquired by Quotient in December 2008, to form a new
strategic business unit within Quotient - Quotient Clinical.
QUOTIENT BIOSCIENCE GROUP FORMS NEW BIODIAGNOSTICS DIVISION
QUOTIENT BIOSCIENCE GROUP FORMS NEW BIODIAGNOSTICS DIVISION: APPOINTS JEREMY STACKAWITZ AS PRESIDENT AND CEO OF QUOTIENT
BIODIAGNOSTICS
NEW! - QUOTIENT INTELLIGENCE NEWSLETTER
**NEW** Quotient Intelligence newsletter - Issue 1 spring 2009
We are very pleased to announce the launch of our new look Intelligence newsletter. Click here to find out more!
ACQUISITION OF PHARMACEUTICAL PROFILES EXPANDS EARLY-PHASE DRUG DEVELOPMENT SERVICE OFFERING
CAMBRIDGESHIRE, UK, 15 December, 2008 – Quotient Bioscience Group Limited (“Quotient”), a leading European provider of analytical and safety evaluation services and products for bioscience and sport, is pleased to announce that it has acquired Pharmaceutical Profiles Group Limited (“Pharmaceutical Profiles”). Pharmaceutical Profiles will become an important member of Quotient’s Drug Development Services Group - Quotient Bioresearch.
Quotient Bioresearch completes a £4.5m investment to create 19,000 ft2 of new purpose built laboratories
CAMBRIDGESHIRE UK, 04 December 2008.
Quotient Bioresearch, a leading provider of early phase drug development and sports testing services, is pleased to announce the completion of a £4.5M, 19,000 ft2 laboratory build project at its Fordham site near Cambridge. Marking an important milestone in the growth of the company, this investment significantly expands Quotient Bioresearch’s facilities to create one of the largest laboratories of its type in the world.
NEXT GENERATION MASS SPECTROMETRY for METABOLITE IDENTIFICATION
NEXT GENERATION MASS SPECTROMETRY for METABOLITE IDENTIFICATION
CAMBRIDGESHIRE, UK, 7 November 2008. Quotient Bioresearch, a leading provider of early phase drug development and sports testing services, today announces that it is investing in its development with the purchase of three Thermo Scientific LTQ Orbitrap™ XL mass spectrometers.This significant investment demonstrates Quotient Bioresearch’s commitment to offering the highest quality service to its customers.
QUOTIENT RECEIVES STRATEGIC INVESTMENT OF £35 MILLION From TA ASSOCIATES
Proceeds to be used to fund aquisition-led and organic growth strategy.
QUOTIENT CONSOLIDATES DRUG DEVELOPMENT BUSINESSES
Businesses now fully integrated and Quotient seeking further acquisitions